What's Happening?
A new medication, baxdrostat, has been found to significantly reduce blood pressure in patients whose levels remain high despite taking multiple existing drugs. This discovery comes from a Phase III clinical trial led by Professor Bryan Williams at the
UCL Institute of Cardiovascular Science. The trial, known as BaxHTN, involved nearly 800 patients across 214 clinics worldwide and was funded by AstraZeneca. The results, presented at the European Society of Cardiology Congress 2025 and published in the New England Journal of Medicine, showed that patients taking baxdrostat experienced an average drop in blood pressure of about 9 to 10 mmHg more than those on a placebo. This reduction is significant enough to lower the risk of cardiovascular events. Baxdrostat works by blocking the production of aldosterone, a hormone that regulates salt and water levels in the body, which in excess can lead to high blood pressure.
Why It's Important?
The development of baxdrostat is a significant advancement in the treatment of hypertension, particularly for patients with resistant high blood pressure. Hypertension affects approximately 1.3 billion people globally, with nearly half of these cases being uncontrolled or poorly responsive to current treatments. This condition increases the risk of heart attack, stroke, kidney disease, and early death. The ability of baxdrostat to effectively lower blood pressure in difficult-to-treat cases offers hope for millions of patients worldwide. The drug's potential to target a key hormone involved in blood pressure regulation could lead to more effective management of hypertension, reducing the global burden of this condition.
What's Next?
The promising results of the BaxHTN trial suggest that baxdrostat could become a vital tool in managing resistant hypertension. Further research and regulatory approvals will be necessary before the drug can be widely available. If approved, baxdrostat could help up to half a billion people globally, including millions in the U.S., achieve better blood pressure control. The findings also highlight the need for continued research into the hormonal causes of hypertension, which could lead to the development of additional targeted therapies.
